Nov. 10, 2018
CHICAGO ‒ The REDUCE-IT cardiovascular outcomes trial results, announced today at the American Heart Association Scientific Sessions in Chicago, met its primary composite endpoint and revealed a reduction in major adverse cardiovascular events (MACE) of 25%.
Download the manuscript online now.
By Batya Swift Yasgur, MA, LMSW
In February of 2016, the National Lipid Association (NLA) released its Annual Summary of Clinical Lipidology, which is an update to Parts 1 and 2 of the NLA's “Recommendations for Patient-Centered Management of Dyslipidemia,” both published in 2015. The summary is unique in that it contains both updated content and a novel format. To shed further light on the changes in the new summary, MPR spoke to Harold E. Bays, MD, who was the lead author.
By Carol Kirkpatrick, PhD, RDN, LDN, CLS, FNLA; Geeta Sikand, MA, RDN, FAND, CLS, CDE, FNLA; Ralph LaForge, MSc, CLS, FNLA
In September, the National Lipid Association released its new Recommendations for Patient-Centered for Dyslipidemia Management – Part 2. These recommendations include a thorough review of the lifestyle therapies — nutrition and physical activity — that promote atherosclerotic CVD risk reduction through lowering atherogenic cholesterol and other atherosclerotic CVD risk factors.
Targets of lifestyle therapies
.jpg)
.png)
